MAP2K7 and lung carcinoma: The same conclusions were drawn from combinations of MDM2 and MEK inhibitors in the RT4 (bladder cancer), RKO (colorectal cancer), A427 (lung cancer), and C32 (melanoma) cell lines (Figure 3C-F).